Trial Profile
Telaprevir or simeprevir-based triple therapy for recurrent hepatitis C virus among living donor liver transplant recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2015
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Oct 2015 Status changed from recruiting to completed, as reported by University Hospital Medical Information Network - Japan.
- 26 Jun 2014 New trial record